Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study

Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study

Abstract Background COVID‐19 incidence is high in patients with cancer. The fatality rate was high for the Delta variant, necessitating infection prevention by vaccination. This study evaluated the safety of a SARS‐CoV‐2 vaccine in patients with advanced lung cancer receiving anticancer therapy. Met...

Full description

Bibliographic Details
Main Authors: Daijiro Harada, Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Yoshinobu Maeda, Katsuyuki Kiura
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Thoracic Cancer
Subjects:
anticancer drugs
COVID‐19
lung cancer
SARS‐CoV‐2
vaccine safety
Online Access:https://doi.org/10.1111/1759-7714.14737

Internet

https://doi.org/10.1111/1759-7714.14737

Similar Items